X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with India Infoline - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs IIFL HOLDINGS - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

IIFL HOLDINGS 
   Change

India Infoline is one of the oldest and leading players in the Indian broking services space. Besides offering the entire gamut of financial services covering investment products ranging from equities and derivatives, commodities and portfolio manage... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES IIFL HOLDINGS INDOCO REMEDIES/
IIFL HOLDINGS
 
P/E (TTM) x 32.6 27.4 118.9% View Chart
P/BV x 3.9 7.5 51.9% View Chart
Dividend Yield % 0.6 0.6 96.7%  

Financials

 INDOCO REMEDIES   IIFL HOLDINGS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
IIFL HOLDINGS
Mar-16
INDOCO REMEDIES/
IIFL HOLDINGS
5-Yr Chart
Click to enlarge
High Rs360226 159.8%   
Low Rs249160 155.5%   
Sales per share (Unadj.) Rs119.0125.9 94.6%  
Earnings per share (Unadj.) Rs8.416.1 51.8%  
Cash flow per share (Unadj.) Rs15.218.2 83.5%  
Dividends per share (Unadj.) Rs1.604.25 37.6%  
Dividend yield (eoy) %0.52.2 23.8%  
Book value per share (Unadj.) Rs70.792.2 76.6%  
Shares outstanding (eoy) m92.15316.54 29.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.61.5 167.1%   
Avg P/E ratio x36.411.9 305.0%  
P/CF ratio (eoy) x20.010.6 189.2%  
Price / Book Value ratio x4.32.1 206.1%  
Dividend payout %19.126.3 72.7%   
Avg Mkt Cap Rs m28,08361,061 46.0%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1677,045 30.8%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,96839,840 27.5%  
Other income Rs m40116 34.2%   
Total revenues Rs m11,00739,957 27.5%   
Gross profit Rs m1,56525,771 6.1%  
Depreciation Rs m633661 95.8%   
Interest Rs m6216,800 0.4%   
Profit before tax Rs m9098,426 10.8%   
Minority Interest Rs m0-436 0.0%   
Prior Period Items Rs m0-42 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1392,836 4.9%   
Profit after tax Rs m7715,112 15.1%  
Gross profit margin %14.364.7 22.1%  
Effective tax rate %15.333.7 45.3%   
Net profit margin %7.012.8 54.8%  
BALANCE SHEET DATA
Current assets Rs m5,725122,903 4.7%   
Current liabilities Rs m5,45496,534 5.6%   
Net working cap to sales %2.566.2 3.7%  
Current ratio x1.01.3 82.4%  
Inventory Days Days623 2,039.3%  
Debtors Days Days7254 133.7%  
Net fixed assets Rs m5,3074,805 110.5%   
Share capital Rs m184633 29.1%   
"Free" reserves Rs m6,33120,773 30.5%   
Net worth Rs m6,51629,200 22.3%   
Long term debt Rs m1,32390,203 1.5%   
Total assets Rs m11,970228,766 5.2%  
Interest coverage x15.61.5 1,041.9%   
Debt to equity ratio x0.23.1 6.6%  
Sales to assets ratio x0.90.2 526.1%   
Return on assets %7.09.6 72.6%  
Return on equity %11.817.5 67.6%  
Return on capital %12.420.7 59.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886-541 -163.9%  
From Investments Rs m-1,706-6,707 25.4%  
From Financial Activity Rs m1,3165,249 25.1%  
Net Cashflow Rs m497-1,999 -24.8%  

Share Holding

Indian Promoters % 59.2 30.7 192.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.8 1,562.5%  
FIIs % 6.0 44.4 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 24.2 92.6%  
Shareholders   12,805 27,982 45.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KOTHARI PRODUCTS  INGERSOLL RAND  FINOLEX IND.  COMMEX TECHNOLOGY  STC INDIA  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 19, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS